English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Sirona Licenses Anti-Diabetic Drug to Wanbang for up-to $9.5 million

Jan. 27, 2014

Sirona Biochem Corp. announced on January 27, 2014 the completion of an exclusive licensing agreement with Wanbang Biopharmaceuticals. Sirona will provide an exclusive license to Wanbang to develop and commercialize Sirona’s anti-diabetic SGLT2 inhibitor in China. In exchange for this license, Wanbang will provide upfront and milestone payments of up to US$9.5M in addition to royalty payments for product sales in the PRC.